Mast Therapeutics (MSTX) : The highest short term price target forecast on Mast Therapeutics (MSTX) is $5 and the lowest target price is $1. A total of 3 equity analysts are currently covering the company. The average price of all the analysts is $2.67 with a standard deviation of $2.08.
Mast Therapeutics (MSTX) reported a rise of 27.9% or 2,812,701 shares in its short interest. The short figure came in at 6.8% of the total floats. The average daily volume of 4,113,883 shares suggests that the days to cover 12,910,857 short positions, as on June 30,2016, will be 3. On June 15,2016, the short interest was 10,098,156 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.
Mast Therapeutics (NYSEMKT:MSTX): On Thursdays trading session , Opening price of the stock was $0.4436 with an intraday high of $0.468. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.4251. However, the stock managed to close at $0.4402, a loss of 0.36% for the day. On the previous day, the stock had closed at $0.4418. The total traded volume of the day was 2,512,903 shares.
Mast Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops therapies for serious or life-threatening diseases with unmet needs. The Company leverages its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, the Companys lead product candidate. Vepoloxamer is being tested in a Phase III clinical study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. AIR001 is being tested in multiple institution-sponsored Phase IIa clinical studies that provide the Company with data on AIR001s potential to treat patients with preserved ejection fraction (HFpEF).